Actinic Keratosis Clinical Trial
Official title:
Pilot Studies Testing the Effect of Topical Imipramine on Pain and Effectiveness of Topical Photodynamic Therapy
NCT number | NCT05688904 |
Other study ID # | 07286 |
Secondary ID | |
Status | Recruiting |
Phase | Phase 1 |
First received | |
Last updated | |
Start date | January 19, 2023 |
Est. completion date | March 2028 |
The purpose of this study is testing the use of topical Imipramine in combination with topical photodynamic therapy's (PDT) effect on pain following treatment. PDT is a commonly used treatment in dermatology for patients who have many pre-cancers (actinic keratosis-AKs) on their skin. These are both FDA-approved treatments, but this study is evaluating their use in combination, which has not been evaluated in the past. The investigators have been doing studies using animals that suggest that imipramine might make the PDT less painful and might help it work better. In order to participate, the subject and their dermatologist have decided that they would benefit from PDT to treat their skin due to many AK precancerous lesions. Please note that neither PDT nor imipramine are experimental treatments, but treating their skin with imipramine before PDT is a new approach.
Status | Recruiting |
Enrollment | 24 |
Est. completion date | March 2028 |
Est. primary completion date | March 2028 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Male or female ages 18 and older - Skin type must be "Fair", Fitzpatrick type I to III, due to the presence of actinic damage in this population. - Subjects need to have a physician's order to receive PDT treatment on their face, scalp or forearms. - Willing to participate and understand the informed consent document. - Willing to avoid excess sun exposure/tanning beds to the area to be treated with PDT. Exclusion Criteria: - Those currently taking any tricyclic antidepressants (TCAs) - Those currently taking any selective serotonin reuptake inhibitor (SSRI) - Those with porphyria - Large tattoos in the treated areas - Pregnancy or nursing - Taking any oral or topical medications that could interfere with the PDT (Appendix A) - Active rashes in the area |
Country | Name | City | State |
---|---|---|---|
United States | Wright State Physicians | Fairborn | Ohio |
Lead Sponsor | Collaborator |
---|---|
Wright State University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of precancerous actinic keratosis present from baseline. | Principal investigator assesses this from AK lesion count mapping at baseline and in 6 months. | 6 months post PDT treatment | |
Secondary | Change in pain level due to photodynamic therapy (PDT) from baseline. | The visual analog pain scale is used to assess this outcome. (0 = no skin pain to 10 = severe skin pain) | Immediately post PDT treatment | |
Secondary | Change in pain level due to photodynamic therapy (PDT) from baseline. | The visual analog pain scale is used to assess this outcome. (0 = no skin pain to 10 = severe skin pain) | 10 minutes post PDT treatment | |
Secondary | Change in pain level due to photodynamic therapy (PDT) from baseline. | The visual analog pain scale is used to assess this outcome. (0 = no skin pain to 10 = severe skin pain) | 30 minutes post PDT treatment | |
Secondary | Change in pain level due to photodynamic therapy (PDT) from baseline. | The visual analog pain scale is used to assess this outcome. (0 = no skin pain to 10 = severe skin pain) | 6 months post PDT treatment | |
Secondary | Change in itch level due to photodynamic therapy (PDT) from baseline. | The visual analog itch scale will be used to assess this outcome. (0 = no skin itch to 10 = severe skin itch) | Immediately post PDT treatment | |
Secondary | Change in itch level due to photodynamic therapy (PDT) from baseline. | The visual analog itch scale will be used to assess this outcome. (0 = no skin itch to 10 = severe skin itch) | 10 minutes post PDT treatment | |
Secondary | Change in itch level due to photodynamic therapy (PDT) from baseline. | The visual analog itch scale will be used to assess this outcome. (0 = no skin itch to 10 = severe skin itch) | 30 minutes post PDT treatment | |
Secondary | Change in itch level due to photodynamic therapy (PDT) from baseline. | The visual analog itch scale will be used to assess this outcome. (0 = no skin itch to 10 = severe skin itch) | 6 months post PDT treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03013647 -
Daylight Photodynamic Therapy for Actinic Keratosis and Skin Field Cancerization
|
N/A | |
Completed |
NCT02674048 -
Metvix Daylight PDT in Actinic Keratosis
|
||
Completed |
NCT02239679 -
Controlled Study of the Occurrence of Actinic Keratosis on the Face After Cryotherapy + Aminolevulinic Acid (ALA) Photodynamic Therapy
|
Phase 2 | |
Completed |
NCT02421471 -
PMS to Evaluate the Safety and Efficacy of Picato® Gel
|
||
Completed |
NCT01686152 -
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
|
Phase 3 | |
Terminated |
NCT01525329 -
Combination Therapy With 5-Fluorouracil and Photodynamic Therapy in Post-transplant Premalignant Skin Disease
|
Phase 3 | |
Completed |
NCT01449513 -
PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Reflectance Confocal Microscopy
|
Phase 1 | |
Completed |
NCT01444989 -
Development and Validation of a Quality of Life Instrument for Actinic Keratosis
|
N/A | |
Terminated |
NCT01203878 -
Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy
|
Phase 4 | |
Completed |
NCT00989313 -
A Long Term Follow up Study of Patients Who Have Complete Clearance of Their Actinic Keratosis (AK) Lesions at the Day 57 Visit in the PEP005-028 Study
|
Phase 3 | |
Completed |
NCT00306800 -
Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp
|
Phase 3 | |
Completed |
NCT00375739 -
Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses
|
Phase 2 | |
Completed |
NCT03285490 -
A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on Actinic Keratosis on Face or Scalp (AK004)
|
Phase 3 | |
Completed |
NCT03319251 -
Biomarker Database Registry for Photodynamic Therapy
|
||
Completed |
NCT02866695 -
Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients
|
Phase 4 | |
Completed |
NCT02952898 -
Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses
|
Phase 3 | |
Completed |
NCT02984072 -
Menthol for PDT Pain Relief
|
Phase 4 | |
Recruiting |
NCT03684772 -
Topical Ionic Contra-Viral Therapy in Actinic Keratosis
|
Phase 2 | |
Completed |
NCT02938715 -
Pilot Study of the Pragmatic Use of Mobile Phone Based Follow up of Actinic Keratoses Treated With Topical 5-fluorouracil
|
N/A | |
Completed |
NCT02878382 -
Potential Impact of Patient Vitamin D Status in AK Response to MAL-PDT
|
N/A |